General Surgery Devices are used in diagnostic and surgical interventions primarily for the gastrointestinal tract, abdomen, and pelvis. Embolization is an intervention that uses particles such as tiny gelatin sponges or beads to block a blood vessel. GlobalData uses proprietary data and analytics to provide a comprehensive report on the embolization particles market in Finland. Buy the latest report here.
Smarter leaders trust GlobalData
In 2023, GlobalData’s Market Model methodology determined that the leading player in the embolization particles market in Finland was Boston Scientific followed by Varian Medical Systems, Merit Medical Systems and Cook Medical.
Understanding market size can be crucial to evaluate opportunities and make informed decisions about market entry and exit. Medical device companies can identify attractive segments in respective markets as well as develop marketing strategies based on forecasts for those segments.
Embolization Particles are used to stop bleeding or to block the flow of blood to a tumor. These particles are generally used to treat liver cancer, renal cell carcinoma, kidney cancer, neuroendocrine tumors, arteriovenous malformation, uterine fibroids and benign prostatic hyperplasia. Despite having similar appearances and handling characteristics, each one of the embolic agents have specific physical and chemical properties that affects their in vivo behavior. Clinicians have to familiarize themselves with these differences to make the correct choice of embolic agent, and then use the correct protocol for embolization. The sizes of embolization particles can range from 30 to 1200 µm, depending on the indication. Embolization Particles include Drug-Eluting Beads, Microspheres, PolyVinyl Alcohol (PVA) Particles, and Radioembolization Particles.
The embolization particles market in Finland can expand or contract due to a variety of reasons including population demographics, disease incidence and prevalence, macroeconomic issues, and geopolitical considerations. Disruption to a market could be caused by a sudden, unexpected change in these factors, but it could also be driven by changes in clinical practice, leading to a change in diagnosis or treatment of patients, as part of a process to generally improve medical practice.
For the latest analysis of the market size embolization particles in Finland, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Medical Intelligence Center Market Models are the gold standard of medical device market valuation, company share estimation and market trend forecasting. GlobalData uses a patient-based forecast model or installed base methodology to determine the market size for therapeutic indications and capital equipment expenditures. Estimates are based on a number of sources, including primary research—KOL and industry contact interviews—and secondary research, such as company reports, press releases, published articles, proprietary databases, and general news media.
